Clin2
NCT06592833Possibly a fitRecruiting

Psilocybin with or without pimavanserin for depression

Major Depressive Disorder

Treatments studied

Part of Mental health clinical trials.

This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
21 years to 80 years
Study type
Interventional

Who can take part

  • You must be between 21 and 80 years old.
  • You must have a current diagnosis of major depressive disorder (without a history of psychosis or bipolar disorder).
  • You must be willing to stop taking certain antidepressants or other serotonergic medications for at least 2 weeks before the study starts.
  • You cannot have used any psychedelic drugs (like LSD, psilocybin, or MDMA) in the past 12 months.
  • You cannot have a significant medical condition, such as heart problems, unstable health issues, or a history of substance use disorder in the last 6 months (excluding tobacco).
  • You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06072898Recruiting· Phase 2
Psilocybin brain imaging trial for depression

This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.

Toronto, Ontario
NCT06247839Recruiting· Phase 3
Psilocybin for depression: changing self-focus

This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.

Charlestown, Massachusetts
NCT07703722Recruiting· Phase 3
Psilocybin and therapy for depression with trauma

This trial tests psilocybin (a compound from certain mushrooms) combined with a structured therapy to see if it helps people with depression linked to trauma. It focuses on how the treatment affects the connection between the gut and brain.

Islamabad, Capital
NCT06442423Recruiting· Phase 1
Psilocybin study for people with psychiatric symptoms

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

New Haven, Connecticut
NCT07610135Recruiting· Phase 1/Phase 2
Psilocybin with or without pimavanserin pretreatment

This trial tests whether taking pimavanserin before psilocybin changes the drug's effects in healthy volunteers who have never used psychedelics. It aims to understand how to make psychedelic therapy safer and more predictable.

Baltimore, Maryland
NCT07281352Recruiting· Phase 1/Phase 2
Psilocybin therapy for depression

This study tests if psilocybin (a psychedelic) combined with cognitive behavioral therapy (CBT) can help people with major depression. You would receive the psilocybin in a supervised setting and have talk therapy before and after.

Los Angeles, California

Hear when a new Major Depressive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.